INVESTOR ALERT
129
0 Kommentare
Law Offices of Howard G. Smith Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors
129 
0 KommentareLaw Offices of Howard G. Smith announces an investigation on behalf of Annovis Bio, Inc. (“Annovis” or the “Company”) (NYSE: ANVS) investors concerning the Company’s possible violations of federal securities laws.
On April 29, 2024, Annovis announced that its Alzheimer’s drug, buntanetap, had shown significant results in a subgroup of patients. However, the subgroup was a fraction of the total planned patients, indicating that the drug failed to show statistical significance in meeting its endpoints.
On this news, Annovis’s stock price fell $10.37, or 59.6%, to close at $7.28 per share on April 29, 2024, thereby injuring investors.
If you purchased Annovis securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847 or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240517681411/en/
The Annovis Bio Stock at the time of publication of the news with a fall of -3,78 % to 7,13EUR on Tradegate stock exchange (17. Mai 2024, 16:17 Uhr).
Aktuelle Themen
Weitere Artikel des Autors
URL kopieren
Per E-Mail teilen
Artikel drucken
Artikel zu den Werten
Auch bei Lesern beliebt
